Page 4 - Adjuvant Setting News Today

Longer-term results from the OlympiA trial show a 32% improvement in overall survival with olaparib among women with early-stage germline BRCA-mutated breast cancer.

KEYTRUDA Is Now Approved as Monotherapy for Adults With RCC at Increased Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions KEYTRUDA Is the First

A blood test that measures circulating tumor DNA can identify patients with colorectal cancer who may derive the most benefit from adjuvant chemotherapy.

Comparable progression-free survival was observed in intermediate-risk patients with HPV and oropharynx cancer who received less intense postoperative radiation therapy, without chemotherapy.

Although dopamine agonists and dopamine reuptake inhibitors (DRIs) may be effective in treating Parkinsons disease and motor fluctuations not controlled with levodopa, not all DRIs are equal.

Lumateperone is now the only FDA-approved drug for depressive episodes associated with bipolar I or II disorder in adults, as monotherapy or an adjunct to lithium or valproate.

Adding a regular yoga regimen to standard therapy can reduce symptoms and improve quality of life in patients with frequent fainting spells, or vasovagal syncope (VVS).

A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.

Metformin as adjuvant therapy did not improve invasive disease-free survival or overall survival rates, regardless of hormone receptor status.

KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC MelanomaKEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III DiseaseKENILWORTH, N.J.-...